Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Jul 12 2014

Volume: 384

Issue: 9938

Affiliations

[1 ] US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: patricia.cortazar@fda.hhs.gov.

[2 ] US Food and Drug Administration, Silver Spring, MD, USA.

[3 ] HELIOS Klinikum, Berlin, Germany.

[4 ] German Breast Group, Neu-Isenburg, Germany.

[5 ] National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA.

[6 ] Institut Bergonié INSERM U916 and Université Bordeaux Segalen, Bordeaux, France.

[7 ] Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, UK.

[8 ] San Raffaele Scientific Institute, Milan, Italy.

[9 ] Fondazione Michelangelo, Milan, Italy.

[10 ] Medstar Washington Hospital Center, Washington, DC, USA.

[11 ] EORTC Headquarters, Brussels, Belgium.

[12 ] Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

[13 ] Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

[14 ] St Gertrauden Hospital, Berlin, Germany.

[15 ] MD Anderson Cancer Center Orlando, Orlando, FL, USA.

[16 ] KarolinskaInstitutet and University Hospital, Stockholm, Sweden.

[17 ] NN Petrov Research Institute of Oncology, St Petersburg, Russia.

[18 ] University Women's Hospital, Kiel, Germany.

[19 ] Jules Bordet Institute, Brussels, Belgium.

[20 ] Frauenklinik des Universitätsklinikums, Erlangen, Germany.

[21 ] Universitäts Frauenklinik, Rostock, Germany.

[22 ] Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.

[23 ] Hospital of the Ludwig Maximilian University of Munich, Munich, Germany.

Article

Publisher Item ID: S0140-6736(13)62422-8

DOI: 10.1016/S0140-6736(13)62422-8

PubMed ID: 24529560

SO-VID: 3d72a40e-1c79-4af4-91f7-6d776d3efa49

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1,482

Breast Cancer Treatment
Authors: Adrienne Waks, Eric Winer
Pembrolizumab for Early Triple-Negative Breast Cancer
Authors: Peter J. Schmid, Javier Cortés, Lajos Pusztai …
Breast cancer
Authors: Michael Gnant, Nadia Harbeck

See all cited by

- Version 1
- Version 1